Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Ségui B[au]:

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma. Bertrand F et al. Nat Commun. (2017)

Glucosylceramidases and malignancies in mammals. Astudillo L et al. Biochimie. (2016)

Chemotherapy with ceramide in TNBC. Legembre P et al. Oncoscience. (2015)

Search results

Items: 1 to 50 of 79

1.

The TNF Paradox in Cancer Progression and Immunotherapy.

Montfort A, Colacios C, Levade T, Andrieu-Abadie N, Meyer N, Ségui B.

Front Immunol. 2019 Jul 31;10:1818. doi: 10.3389/fimmu.2019.01818. eCollection 2019. No abstract available.

2.

Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma.

Bilal F, Montfort A, Gilhodes J, Garcia V, Riond J, Carpentier S, Filleron T, Colacios C, Levade T, Daher A, Meyer N, Andrieu-Abadie N, Ségui B.

Front Pharmacol. 2019 Apr 30;10:443. doi: 10.3389/fphar.2019.00443. eCollection 2019.

3.

Morniga-G, a T/Tn-Specific Lectin, Induces Leukemic Cell Death via Caspase and DR5 Receptor-Dependent Pathways.

Poiroux G, Barre A, Simplicien M, Pelofy S, Segui B, Van Damme EJM, Rougé P, Benoist H.

Int J Mol Sci. 2019 Jan 8;20(1). pii: E230. doi: 10.3390/ijms20010230.

4.

IL13-Mediated Dectin-1 and Mannose Receptor Overexpression Promotes Macrophage Antitumor Activities through Recognition of Sialylated Tumor Cells.

Alaeddine M, Prat M, Poinsot V, Gouazé-Andersson V, Authier H, Meunier E, Lefèvre L, Alric C, Dardenne C, Bernad J, Alric L, Segui B, Balard P, Couderc F, Couderc B, Pipy B, Coste A.

Cancer Immunol Res. 2019 Feb;7(2):321-334. doi: 10.1158/2326-6066.CIR-18-0213. Epub 2019 Jan 4.

PMID:
30610060
5.

Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas.

Garandeau D, Noujarède J, Leclerc J, Imbert C, Garcia V, Bats ML, Rambow F, Gilhodes J, Filleron T, Meyer N, Brayer S, Arcucci S, Tartare-Deckert S, Ségui B, Marine JC, Levade T, Bertolotto C, Andrieu-Abadie N.

Mol Cancer Ther. 2019 Feb;18(2):289-300. doi: 10.1158/1535-7163.MCT-17-1141. Epub 2018 Nov 27.

PMID:
30482853
6.

[Anti-TNFα antibodies in melanoma immunotherapy].

Montfort A, Colacios C, Levade T, Andrieu-Abadie N, Meyer N, Ségui B.

Med Sci (Paris). 2018 Oct;34(10):788-791. doi: 10.1051/medsci/2018202. Epub 2018 Nov 19. French. No abstract available.

PMID:
30451663
7.

Prostatitis, other genitourinary infections and prostate cancer risk: Influence of non-steroidal anti-inflammatory drugs? Results from the EPICAP study.

Doat S, Marous M, Rebillard X, Trétarre B, Lamy PJ, Soares P, Delbos O, Thuret R, Segui B, Cénée S, Menegaux F.

Int J Cancer. 2018 Apr 26. doi: 10.1002/ijc.31565. [Epub ahead of print]

8.

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma.

Bertrand F, Montfort A, Marcheteau E, Imbert C, Gilhodes J, Filleron T, Rochaix P, Andrieu-Abadie N, Levade T, Meyer N, Colacios C, Ségui B.

Nat Commun. 2017 Dec 22;8(1):2256. doi: 10.1038/s41467-017-02358-7.

9.

S1P: the elixir of life for naive T cells.

Pérès M, Montfort A, Andrieu-Abadie N, Colacios C, Ségui B.

Cell Mol Immunol. 2018 Jul;15(7):657-659. doi: 10.1038/cmi.2017.110. Epub 2017 Oct 30. No abstract available.

10.

Liquid Chromatography-High Resolution Mass Spectrometry Method to Study Sphingolipid Metabolism Changes in Response to CD95L.

Bilal F, Pérès M, Le Faouder P, Dupuy A, Bertrand-Michel J, Andrieu-Abadie N, Levade T, Badran B, Daher A, Ségui B.

Methods Mol Biol. 2017;1557:213-217. doi: 10.1007/978-1-4939-6780-3_20.

PMID:
28078596
11.

Method to Measure Sphingomyelin Synthase Activity Changes in Response to CD95L.

Bilal F, Pérès M, Andrieu-Abadie N, Levade T, Badran B, Daher A, Ségui B.

Methods Mol Biol. 2017;1557:207-212. doi: 10.1007/978-1-4939-6780-3_19.

PMID:
28078595
12.

Downregulation of sphingosine kinase-1 induces protective tumor immunity by promoting M1 macrophage response in melanoma.

Mrad M, Imbert C, Garcia V, Rambow F, Therville N, Carpentier S, Ségui B, Levade T, Azar R, Marine JC, Diab-Assaf M, Colacios C, Andrieu-Abadie N.

Oncotarget. 2016 Nov 1;7(44):71873-71886. doi: 10.18632/oncotarget.12380.

13.

Targeting TNF alpha as a novel strategy to enhance CD8+ T cell-dependent immune response in melanoma?

Bertrand F, Rochotte J, Colacios C, Montfort A, Andrieu-Abadie N, Levade T, Benoist H, Ségui B.

Oncoimmunology. 2015 Aug 12;5(1):e1068495. eCollection 2016.

14.

Chemotherapy with ceramide in TNBC.

Legembre P, Micheau O, Ségui B.

Oncoscience. 2015 Aug 21;2(10):817-8. eCollection 2015. No abstract available.

15.

TNF-R1, an immune checkpoint in melanoma?

Bertrand F, Colacios C, Ségui B.

Genes Cancer. 2015 Sep;6(9-10):369-70. No abstract available.

16.

Glucosylceramidases and malignancies in mammals.

Astudillo L, Therville N, Colacios C, Ségui B, Andrieu-Abadie N, Levade T.

Biochimie. 2016 Jun;125:267-80. doi: 10.1016/j.biochi.2015.11.009. Epub 2015 Nov 12. Review.

PMID:
26582417
17.

Evaluation of the foetal time to death in mice after application of direct and indirect euthanasia methods.

Muñoz-Mediavilla C, Cámara JA, Salazar S, Segui B, Sanguino D, Mulero F, de la Cueva E, Blanco I.

Lab Anim. 2016 Apr;50(2):100-7. doi: 10.1177/0023677215600626. Epub 2015 Aug 11.

PMID:
26265244
18.

Blocking Tumor Necrosis Factor α Enhances CD8 T-cell-Dependent Immunity in Experimental Melanoma.

Bertrand F, Rochotte J, Colacios C, Montfort A, Tilkin-Mariamé AF, Touriol C, Rochaix P, Lajoie-Mazenc I, Andrieu-Abadie N, Levade T, Benoist H, Ségui B.

Cancer Res. 2015 Jul 1;75(13):2619-28. doi: 10.1158/0008-5472.CAN-14-2524. Epub 2015 May 14.

19.

Monogenic neurological disorders of sphingolipid metabolism.

Sabourdy F, Astudillo L, Colacios C, Dubot P, Mrad M, Ségui B, Andrieu-Abadie N, Levade T.

Biochim Biophys Acta. 2015 Aug;1851(8):1040-51. doi: 10.1016/j.bbalip.2015.01.010. Epub 2015 Feb 7. Review.

PMID:
25660725
20.

Sphingolipids modulate the epithelial-mesenchymal transition in cancer.

Levade T, Andrieu-Abadie N, Micheau O, Legembre P, Ségui B.

Cell Death Discov. 2015 Oct 12;1:15001. doi: 10.1038/cddiscovery.2015.1. eCollection 2015. No abstract available.

21.

Human genetic disorders of sphingolipid biosynthesis.

Astudillo L, Sabourdy F, Therville N, Bode H, Ségui B, Andrieu-Abadie N, Hornemann T, Levade T.

J Inherit Metab Dis. 2015 Jan;38(1):65-76. doi: 10.1007/s10545-014-9736-1. Epub 2014 Aug 21. Review.

PMID:
25141825
22.

Downregulation of ceramide synthase-6 during epithelial-to-mesenchymal transition reduces plasma membrane fluidity and cancer cell motility.

Edmond V, Dufour F, Poiroux G, Shoji K, Malleter M, Fouqué A, Tauzin S, Rimokh R, Sergent O, Penna A, Dupuy A, Levade T, Theret N, Micheau O, Ségui B, Legembre P.

Oncogene. 2015 Feb 19;34(8):996-1005. doi: 10.1038/onc.2014.55. Epub 2014 Mar 17.

PMID:
24632610
23.

Impact of preoperative immunonutrition on morbidity following cystectomy for bladder cancer: a case-control pilot study.

Bertrand J, Siegler N, Murez T, Poinas G, Segui B, Ayuso D, Gres P, Wagner L, Thuret R, Costa P, Droupy S.

World J Urol. 2014 Feb;32(1):233-7. doi: 10.1007/s00345-013-1229-6. Epub 2013 Dec 21.

PMID:
24362882
24.

Dual role of sphingosine kinase-1 in promoting the differentiation of dermal fibroblasts and the dissemination of melanoma cells.

Albinet V, Bats ML, Huwiler A, Rochaix P, Chevreau C, Ségui B, Levade T, Andrieu-Abadie N.

Oncogene. 2014 Jun 26;33(26):3364-73. doi: 10.1038/onc.2013.303. Epub 2013 Jul 29.

PMID:
23893239
25.

Phosphorylation of serine palmitoyltransferase long chain-1 (SPTLC1) on tyrosine 164 inhibits its activity and promotes cell survival.

Taouji S, Higa A, Delom F, Palcy S, Mahon FX, Pasquet JM, Bossé R, Ségui B, Chevet E.

J Biol Chem. 2013 Jun 14;288(24):17190-201. doi: 10.1074/jbc.M112.409185. Epub 2013 Apr 29.

26.

Genetic disorders of simple sphingolipid metabolism.

Albinet V, Bats ML, Bedia C, Sabourdy F, Garcia V, Ségui B, Andrieu-Abadie N, Hornemann T, Levade T.

Handb Exp Pharmacol. 2013;(215):127-52. doi: 10.1007/978-3-7091-1368-4_7. Review.

PMID:
23579453
27.

The nonlysosomal β-glucosidase GBA2 promotes endoplasmic reticulum stress and impairs tumorigenicity of human melanoma cells.

Sorli SC, Colié S, Albinet V, Dubrac A, Touriol C, Guilbaud N, Bedia C, Fabriàs G, Casas J, Ségui B, Levade T, Andrieu-Abadie N.

FASEB J. 2013 Feb;27(2):489-98. doi: 10.1096/fj.12-215152. Epub 2012 Oct 16.

PMID:
23073830
28.

The pro-inflammatory action of tumour necrosis factor-α in non-alcoholic steatohepatitis is independent of the NSMAF gene product.

Mas E, Danjoux M, Garcia V, Carpentier S, Ségui B, Levade T.

Dig Liver Dis. 2013 Feb;45(2):147-54. doi: 10.1016/j.dld.2012.09.002. Epub 2012 Oct 6.

PMID:
23044079
29.

The tricyclodecan-9-yl-xanthogenate D609 triggers ceramide increase and enhances FasL-induced caspase-dependent and -independent cell death in T lymphocytes.

Milhas D, Andrieu-Abadie N, Levade T, Benoist H, Ségui B.

Int J Mol Sci. 2012;13(7):8834-52. doi: 10.3390/ijms13078834. Epub 2012 Jul 16.

30.

Ordering of ceramide formation and caspase-9 activation in CD95L-induced Jurkat leukemia T cell apoptosis.

Lafont E, Dupont R, Andrieu-Abadie N, Okazaki T, Schulze-Osthoff K, Levade T, Benoist H, Ségui B.

Biochim Biophys Acta. 2012 Apr;1821(4):684-93. doi: 10.1016/j.bbalip.2012.01.012. Epub 2012 Jan 28.

PMID:
22306364
31.

CD95 triggers Orai1-mediated localized Ca2+ entry, regulates recruitment of protein kinase C (PKC) β2, and prevents death-inducing signaling complex formation.

Khadra N, Bresson-Bepoldin L, Penna A, Chaigne-Delalande B, Ségui B, Levade T, Vacher AM, Reiffers J, Ducret T, Moreau JF, Cahalan MD, Vacher P, Legembre P.

Proc Natl Acad Sci U S A. 2011 Nov 22;108(47):19072-7. doi: 10.1073/pnas.1116946108. Epub 2011 Nov 7.

32.

Targeting of T/Tn antigens with a plant lectin to kill human leukemia cells by photochemotherapy.

Poiroux G, Pitié M, Culerrier R, Lafont E, Ségui B, Van Damme EJ, Peumans WJ, Bernadou J, Levade T, Rougé P, Barre A, Benoist H.

PLoS One. 2011;6(8):e23315. doi: 10.1371/journal.pone.0023315. Epub 2011 Aug 17.

33.

Regulation of death and growth signals at the plasma membrane by sphingomyelin synthesis: implications for hematological malignancies.

Lafont E, Kitatani K, Okazaki T, Ségui B.

Recent Pat Anticancer Drug Discov. 2011 Sep;6(3):324-33. doi: 10.2174/157489211796957801. Review.

PMID:
21762071
34.

Is active acid sphingomyelinase required for the antiproliferative response to rituximab?

Sabourdy F, Selves J, Astudillo L, Laurent C, Brousset P, Delisle MB, Therville N, Andrieu-Abadie N, Ségui B, Recher C, Levade T.

Blood. 2011 Mar 31;117(13):3695-6. doi: 10.1182/blood-2010-11-318493. No abstract available.

PMID:
21454466
35.

Morniga G: a plant lectin as an endocytic ligand for photosensitizer molecule targeting toward tumor-associated T/Tn antigens.

Poiroux G, Pitié M, Culerrier R, Ségui B, Van Damme EJ, Peumans WJ, Bernadou J, Levade T, Rougé P, Barre A, Benoist H.

Photochem Photobiol. 2011 Mar-Apr;87(2):370-7. doi: 10.1111/j.1751-1097.2010.00858.x. Epub 2010 Dec 8.

PMID:
21143236
36.

Caspase-10-dependent cell death in Fas/CD95 signalling is not abrogated by caspase inhibitor zVAD-fmk.

Lafont E, Milhas D, Teissié J, Therville N, Andrieu-Abadie N, Levade T, Benoist H, Ségui B.

PLoS One. 2010 Oct 26;5(10):e13638. doi: 10.1371/journal.pone.0013638.

37.

Apolipoprotein E-deficient mice develop an anti-Chlamydophila pneumoniae T helper 2 response and resist vascular infection.

Nazzal D, Therville N, Yacoub-Youssef H, Garcia V, Thomsen M, Levade T, Segui B, Benoist H.

J Infect Dis. 2010 Sep 1;202(5):782-90. doi: 10.1086/655700.

PMID:
20632890
38.

FAN (factor associated with neutral sphingomyelinase activation), a moonlighting protein in TNF-R1 signaling.

Montfort A, Martin PG, Levade T, Benoist H, Ségui B.

J Leukoc Biol. 2010 Nov;88(5):897-903. doi: 10.1189/jlb.0410188. Epub 2010 Jun 9.

PMID:
20534702
39.

[Histological features and principles of treating testicle tumors in the elderly subject].

Camparo P, Durand X, Avances C, Culine S, Segui B, Rigaud J; Membres du GELU-Groupe d'Etude des Lésions Urologiques; Membres du CCAFU.

Prog Urol. 2009 Nov;19 Suppl 3:S142-6. doi: 10.1016/S1166-7087(09)73361-5. French.

PMID:
20123499
40.

IL-6 deficiency attenuates murine diet-induced non-alcoholic steatohepatitis.

Mas E, Danjoux M, Garcia V, Carpentier S, Ségui B, Levade T.

PLoS One. 2009 Nov 20;4(11):e7929. doi: 10.1371/journal.pone.0007929.

41.

FAN stimulates TNF(alpha)-induced gene expression, leukocyte recruitment, and humoral response.

Montfort A, de Badts B, Douin-Echinard V, Martin PG, Iacovoni J, Nevoit C, Therville N, Garcia V, Bertrand MA, Bessières MH, Trombe MC, Levade T, Benoist H, Ségui B.

J Immunol. 2009 Oct 15;183(8):5369-78. doi: 10.4049/jimmunol.0803384. Epub 2009 Sep 28.

42.

Caspase-mediated inhibition of sphingomyelin synthesis is involved in FasL-triggered cell death.

Lafont E, Milhas D, Carpentier S, Garcia V, Jin ZX, Umehara H, Okazaki T, Schulze-Osthoff K, Levade T, Benoist H, Ségui B.

Cell Death Differ. 2010 Apr;17(4):642-54. doi: 10.1038/cdd.2009.130. Epub 2009 Sep 25.

43.

Redistribution of CD95 into the lipid rafts to treat cancer cells?

Segui B, Legembre P.

Recent Pat Anticancer Drug Discov. 2010 Jan;5(1):22-8. Review.

PMID:
19663773
44.

Two structurally identical mannose-specific jacalin-related lectins display different effects on human T lymphocyte activation and cell death.

Benoist H, Culerrier R, Poiroux G, Ségui B, Jauneau A, Van Damme EJ, Peumans WJ, Barre A, Rougé P.

J Leukoc Biol. 2009 Jul;86(1):103-14. doi: 10.1189/jlb.0708434. Epub 2009 Apr 28.

PMID:
19401384
45.

Interleukin-6 deficiency fails to prevent chronic rejection after aortic allografts in apolipoprotein E-deficient mice.

Yacoub-Youssef H, Blaes N, Calise D, Thiers JC, Therville N, Benoist H, Ségui B, Al Saati T, Thomsen M.

J Heart Lung Transplant. 2009 Jan;28(1):85-92. doi: 10.1016/j.healun.2008.06.012. Epub 2008 Sep 27.

PMID:
19134536
46.

OPA1 cleavage depends on decreased mitochondrial ATP level and bivalent metals.

Baricault L, Ségui B, Guégand L, Olichon A, Valette A, Larminat F, Lenaers G.

Exp Cell Res. 2007 Oct 15;313(17):3800-8. Epub 2007 Aug 19.

PMID:
17826766
47.

Cleavage and cytoplasmic relocalization of histone deacetylase 3 are important for apoptosis progression.

Escaffit F, Vaute O, Chevillard-Briet M, Segui B, Takami Y, Nakayama T, Trouche D.

Mol Cell Biol. 2007 Jan;27(2):554-67. Epub 2006 Nov 13.

48.

Sphingolipids as modulators of cancer cell death: potential therapeutic targets.

Ségui B, Andrieu-Abadie N, Jaffrézou JP, Benoist H, Levade T.

Biochim Biophys Acta. 2006 Dec;1758(12):2104-20. Epub 2006 Jun 6. Review.

49.

[What is the objective of second-line chemotherapy after failure of first-line chemotherapy in hormone-resistant metastatic prostate?].

El Demery M, Pouessel D, Avancès C, Iborra F, Rebillard X, Faix A, Ségui B, Delbos O, Ayuso D, Culine S.

Prog Urol. 2006 Jun;16(3):320-3. French.

PMID:
16821344
50.

Multiple human mesenteric arterial grafts from the same donor to study human chronic vascular rejection in humanized SCID/beige mice.

Marcheix B, Yacoub-Youssef H, Calise D, Thiers JC, Therville N, Benoist H, Blaes N, Ségui B, Game X, Dambrin C, Thomsen M.

J Heart Lung Transplant. 2006 Jun;25(6):675-82. Epub 2006 May 2.

PMID:
16730573

Supplemental Content

Support Center